Braveheart

Clinical-stage biotech developing precision therapy for hypertrophic cardiomyopathy and related conditions

a16zActive

What they do

Problem

Patients with hypertrophic cardiomyopathy and related conditions lack sufficiently targeted, precision treatments to address their disease.

Solution

The company develops precision therapies for hypertrophic cardiomyopathy and related cardiac conditions in clinical-stage development.

Who it's for

Cardiologists and specialty care providers who treat patients with hypertrophic cardiomyopathy (via prescribing and clinical use).